NCT07824167
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Start date pushed from Sep 2026 to Nov 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Geometric mean concentration (GMC) of serum RSV pre-fusion (preF) binding IgG antibodies
Timeframe: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
Geometric mean concentration (GMC) of nasal RSV pre-fusion (preF) binding IgG antibodies
Timeframe: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
Geometric mean titers (GMT) of serum RSV-A neutralizing antibodies
Timeframe: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
Secondary (2)
Serum Geometric mean concentration (GMC) of clesrovimab
Urea-normalized GMC of clesrovimab in the nasal mucosa
Arms and interventions
Infants Receiving Clesrovimab (Enflonsia™)Experimental
Participants will receive a single injection of clesrovimab intramuscularly in the anterolateral thigh at a dose of 105 mg, at Visit 1 (Day 1).
Biologicals: Clesrovimab
Sites
1 site in 1 country
- Emory Children's Center-Vaccine Research ClinicAtlanta, Georgia, United States